Idorsia (IDIA) investor relations material

Executive summary

• QUVIVIQ sales rose 62% year-over-year to CHF 91 million in H1 2026, driven by strong momentum in Europe, Canada, and a return to growth in the U.S., with expanded market access and geographic reach.

• Four key growth drivers: maximizing QUVIVIQ in insomnia, expanding daridorexant beyond insomnia, unlocking TRYVIO/JERAYGO, and advancing a broad innovation pipeline.

• Leadership transition to Roland Wandeler as CEO effective October 1, 2026, bringing scientific and commercial expertise.

• Net revenue for H1 2026 was CHF 110.3 million, down from CHF 131.1 million year-over-year, due to lower contract revenue despite higher product sales.

• US GAAP net loss was CHF 152.7 million in H1 2026, compared to net income of CHF 51.7 million in the prior year, reflecting higher financial expenses and a significant debt extinguishment loss.

Financial highlights

• QUVIVIQ product sales (excluding partner sales) rose from CHF 56 million in H1 2025 to CHF 91 million in H1 2026, mainly from the EUCAN region.

• Product sales increased to CHF 97.4 million from CHF 57.8 million, offset by a sharp decline in contract revenue to CHF 12.8 million from CHF 73.3 million.

• Non-GAAP contract revenue of CHF 8 million from upfront payments for QUVIVIQ licenses in Latin America and Middle East.

• Non-GAAP EBIT loss of CHF 54 million in H1 2026; US GAAP operating loss CHF 63 million.

• Liquidity at end of June 2026 was CHF 89 million, with access to an additional CHF 100 million term loan.

Outlook and guidance

• Full-year 2026 guidance reaffirmed: QUVIVIQ sales expected at CHF 200 million, non-GAAP operating expenses ~CHF 330 million, and non-GAAP operating loss ~CHF 120 million.

• Cash runway extends into 2028 with current liquidity and undrawn facilities.

• TRYVIO/JERAYGO revenues and investments excluded from guidance, pending partnership agreements.